Search our website

Press Releases

VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
September 21st, 2022
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
September 15th, 2022
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
September 8th, 2022
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8th, 2022
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
July 12th, 2022
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
June 28th, 2022
VBI Vaccines Announces Results of Annual General Meeting
June 22nd, 2022
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
June 22nd, 2022
VBI Vaccines to Participate in the Jefferies Healthcare Conference
June 7th, 2022
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
June 6th, 2022
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
June 1st, 2022
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
May 26th, 2022
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022
May 19th, 2022
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 9th, 2022
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
May 2nd, 2022
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting
April 28th, 2022
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
April 5th, 2022
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
March 29th, 2022
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
March 15th, 2022
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022
March 7th, 2022

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top